Below are current clinical trials.12 studies in Pulmonary hypertension
(open studies only).
Filter this list of studies by location, status and more.
The purpose of the United States Pulmonary Hypertension Scientific Registry (USPHSR) will be to promote a greater understanding of PAH in an era of genetic discoveries, the study of the physical make up of individual people, and new treatments through education and collaborative assessment of information among pulmonary hypertension (PH) centers throughout the U.S. The development of a national USPHSR Registry will be an important element for advancement of the understanding of PAH and improvement of the care of patients who suffer from this life threatening disorder.
24-week study to evaluate the efficacy and safety of macitentan for the treatment of portopulmonary hypertension.
We propose to develop a biorepository of plasma samples from patients with suspected and confirmed portopulmonary hypertension to improve our understanding of this disease and its response to pulmonary arterial hypertension targeted therapy and liver transplantation.
The PHAR is a multicenter, prospective registry of newly evaluated patients at PHCCs in the United States who have either PAH or CTEPH. Baseline information will be collected at the time of initial evaluation at the PHCC with follow-up data collected at approximately 6-month intervals.
The purpose of this study is to identify the molecular basis of various forms of heart and lung disease, particularly those that have varying degrees of pulmonary hypertension, pulmonary vascular remodeling, and right ventricular dysfunction.
The purpose of this study is to determine the usefulness of palliative care consultations by a specialty physician and a pulmonologist for patients who have advanced lung disease.
The enormous and rapidly growing burden of Heart Failure with Preserved Ejection Fraction (HFpEF) has led to a need to understand the pathogenesis and treatment options for this morbid disease. Recent research from the investigator's group and others have shown that pulmonary hypertension (PH) is highly prevalent in HFpEF, and right ventricular (RV) dysfunction is present in both early and advanced stages of HFpEF.
These abnormalities in the RV and pulmonary vasculature are coupled with limitations in pulmonary vasodilation during exercise. There are no therapies directly targeted at the pulmonary vasculature that have been clearly shown to be effective in HFpEF. A recent study by Mayo Clinic Investigators has demonstrated pulmonary vasodilation with dobutamine (a beta 2 agonist) in HFpEF. As an intravenous therapy, this is not feasible for outpatient use.
In the proposed randomized, placebo-controlled double blinded trial, the investigators seek to evaluate whether the commonly used inhaled bronchodilator albuterol (a beta 2 agonist), administered through a high-efficiency nebulizer device that achieves true alveolar drug delivery, improves pulmonary vascular resistance (PVR) at rest and during exercise in patients with HFpEF as compared to placebo. This has the potential to lead to a simple cost effective intervention to improve symptoms in HFpEF, and potentially be tested in other World Health Organization (WHO) Pulmonary Hypertension groups. PVR is an excellent surrogate marker for pulmonary vasodilation and has been used in previous early trials of PH therapy.
The purpose of this study is to evaluate the safety, tolerability, and effectiveness of ubenimex in patients who have pulmonary arterial hypertension, to improve exercise capacity and delay clinical worsening.
Scottsdale/Phoenix, Ariz., Rochester, Minn.
The purpose of this study is to determine if non-invasive measurement of blood flow to the lungs and the movement of gas from the lungs to the blood stream at rest and in response to low to moderate intensity exercise can be used as an assessment tool to allow for earlier detection and monitoring of individuals with pulmonary-arterial hypertension, and the response to drug treatments.
STUDY OBJECTIVES Primary objective(s) To evaluate the effect of macitentan 10 mg on pulmonary vascular resistance (PVR) as compared to placebo in subjects with pulmonary hypertension (PH) after left ventricular assist device (LVAD) implantation.
Secondary objectives To evaluate the effect of macitentan 10 mg as compared to placebo on cardio-pulmonary hemodynamics and disease severity in subjects with PH after LVAD implantation.
To evaluate the safety and tolerability of macitentan 10 mg in subjects with PH after LVAD implantation.
Exploratory objectives To explore the potential effect of macitentan 10 mg as compared to placebo on right ventricular function in subjects with PH after LVAD implantation.
To explore the potential effect of macitentan 10 mg as compared to placebo on selected clinical events in subjects with PH after LVAD implantation.
To explore the potential effect of macitentan 10 mg as compared to placebo on renal function as measured by glomerular filtration rate (GFR) in subjects with PH after LVAD implantation.
March 22, 2016
- What is pulmonary hypertension? American Heart Association. http://www.heart.org/HEARTORG/Conditions/HighBloodPressure/AboutHighBloodPressure/What-is-Pulmonary-Hypertension_UCM_301792_Article.jsp#.Vmc3b9iFPmI. Accessed Dec. 2, 2015.
- What is pulmonary hypertension? National Heart, Lung, and Blood Institute. http://www.nhlbi.nih.gov/health/health-topics/topics/pah. Accessed Dec. 1, 2015.
- McLaughlin VV, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension. Journal of the American College of Cardiology. 2009;53:1573.
- Rubin LJ, et al. Overview of pulmonary hypertension in adults. http://www.uptodate.com/home. Accessed Nov. 11, 2015.
- Rubin LJ, et al. Clinical features and diagnosis of pulmonary hypertension in adults. http://www.uptodate.com/home. Accessed Nov. 11, 2015.
- Connolly HM. Evaluation and prognosis of Eisenmenger syndrome. http://www.uptodate.com/home. Accessed Dec. 2, 2015.
- Fuster V, et al., eds. Pulmonary hypertension. In: Hurst's The Heart. 13th ed. New York, N.Y.: The McGraw-Hill Companies; 2011. http://www.accessmedicine.com. Accessed Nov. 11, 2015.
- Pulmonary hypertension. Merck Manual Professional Version. http://www.merckmanuals.com/professional/pulmonary-disorders/pulmonary-hypertension. Accessed Dec. 3, 2015.
- Cor pulmonale. Merck Manual Professional Version. http://www.merckmanuals.com/professional/cardiovascular-disorders/heart-failure/cor-pulmonale. Accessed Dec. 3, 2015.
- Barbara Woodward Lips Patient Education Center. Pulmonary hypertension. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2015.
- Simonneau G, et al. Updated clinical classification of pulmonary hypertension. Journal of the American College of Cardiology. 2013;62:D34.
- AskMayoExpert. Pulmonary hypertension. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2014.
- Hopkins W, et al. Treatment of pulmonary hypertension in adults. http://www.uptodate.com/home. Accessed Nov. 11, 2015.
- Riggin EA. Allscripts EPSi. Mayo Clinic, Rochester, Minn. Accessed Oct. 21, 2015.
- Mankad R (expert opinion). Mayo Clinic, Rochester, Minn. Jan. 12, 2016.
- McCully RB (expert opinion). Mayo Clinic, Rochester, Minn. Jan. 12, 2016.